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Red blood cell (RBC) transfusions have become an integral 
part of intensive care treatment in critically ill dogs. To 
ensure safe and efficient transfusions, blood group determi-
nation is recommended not only in human beings but also in 
dogs.17 Blood types are genetic markers on the surface of 
RBCs; a set of 2 to several alleles at 1 gene locus makes up a 
blood group system. The canine blood type classification 
uses the dog erythrocyte antigen (DEA) system; a number is 
used to represent the blood group system or the blood type 
(Vriesendorp HM, Westerbroek DL, D’Amaro J, et al.: 1973, 
Joint report of 1st International Workshop on Canine 
Immunogenetics. Tissue Antigens 3:145–163; Vriesendorp 
HM, Albert ED, Templeton JW, et al.: 1976, Joint report of 
the 2nd International Workshop of Canine Immunogenetics. 
Transplant Proc 8:289–314). More than 12 blood group sys-
tems have been recognized in dogs.3,6,9 Most of these blood 
group systems have 2 alleles, which means a dog can be 
positive or negative for that blood type. The DEA 1.0 system 
contains 3 antigens, DEA 1.1, DEA 1.2, and DEA 1.3, and a 
null type (equivalent to Aa1, Aa2, Aa3, and A–).15,16 A null 
phenotype means that the dog does not carry genes for 
expression of the antigen. Dog erythrocyte antigen 1.1 is the 
most common antigen in this system and is expressed by the 
RBCs of approximately 45%–64% of dogs in different 
countries.12,14
In dogs, no clinically important, naturally occurring allo-
antibodies against RBC antigens have been detected. An 
acute hemolytic transfusion reaction in a dog receiving its 
first transfusion has not been reported. However, if blood 
type–incompatible RBC transfusions are administered, allo-
antibody production can be induced.3 Dog erythrocyte anti-
gen 1.1 seems to be the most antigenic canine blood type. 
Transfusion of DEA 1.1–positive erythrocytes to a DEA 
1.1–negative dog will lead to the formation of alloantibodies 
within approximately 4 days.1 An acute life-threatening 
hemolytic transfusion reaction has been documented in a 
sensitized DEA 1.1–negative dog transfused with DEA 
1.1–positive blood.7 If a female dog has received a mis-
matched RBC transfusion prior to whelping, alloantibodies 
in the colostrum might possibly cause alloimmune hemolytic 
anemia (neonatal isoerythrolysis) in neonatal puppies.4,10,18
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Abstract. In transfusion medicine, blood typing is an integral part of pretransfusion testing. The objective of the current 
study was the clinical evaluation of an automated canine cartridge dog erythrocyte antigen (DEA) 1.1 blood-typing method 
(QuickVet/RapidVet) and comparison of the results with a gel column–based method (ID-Gel Test Canine DEA 1.1). 
Ethylenediamine tetra-acetic acid–anticoagulated blood samples from 11 healthy and 85 sick dogs were available for typing. 
Before blood typing, all samples were tested for agglutination and hemolysis. All samples were tested once or multiple times 
with both methods according to the manufacturer’s guidelines. With the gel method, 53 dogs tested DEA 1.1 positive and 
42 dogs DEA 1.1 negative; blood typing was not possible due to erythrocyte autoagglutination in 1 dog. With the cartridge test, 
53 samples tested DEA 1.1 positive, 34 samples tested DEA 1.1 negative, and 6 results were inconclusive (3 samples were not 
included due to autoagglutination or severe hemolysis). Without taking the inconclusive samples into account, the agreement 
between both methods was 96.5%. The sensitivity and specificity for samples that were definitively typed by both methods 
were 100% and 91.9%, respectively. The cartridge test was suitable for in-clinic canine DEA 1.1 blood typing, although some 
discrepancies compared to the gel method existed. The cartridge test is software-directed, is easy to use, and does not require 
user interpretation, but preanalytical guidelines (sample evaluation for agglutination and hemolysis) have to be followed. For 
inconclusive results, an alternate blood-typing method should be performed.
Key words: Automated blood typing; blood groups; canine transfusion medicine.
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Blood types other than DEA 1.1 seem to be less antigenic. 
However, severe hemolytic transfusion reactions have been 
reported in response to DEA 4 and to an unidentified com-
mon RBC membrane antigen.5,13 A fatal hemolytic transfusion 
reaction occurred in a dog receiving 3 DEA 1.1–compatible 
transfusions; a cross-match prior to the third transfusion was 
not performed (unpublished observation). Therefore, a cross-
match test prior to transfusion is strongly recommended in 
dogs that have received their first transfusion more than 
4 days previously.
The availability of canine blood-typing reagents is lim-
ited, and typing against blood types other than DEA 1.1 is 
only offered by specialized laboratories (Animal Blood 
Resources International, Stockbridge, Michigan). Since the 
mid-1990s, blood-typing cards for DEA 1.1a have been com-
mercially available, enabling typing for DEA 1.1 in clinical 
practice (Seth M, Winzelberg S, Jackson KV, Giger U: 2008, 
Comparison of gel column, card, and cartridge techniques 
for DEA 1.1 blood typing of dogs. J Vet Intern Med 22:775. 
Abstract).8,11 The principle of this card-based agglutination 
test and all other DEA 1.1 blood-typing methods is a visible 
hemagglutination reaction resulting from the binding of the 
DEA 1.1 RBC surface antigen to antibodies. The antibody 
used for the card test is a monoclonal antibody developed by 
the Kansas State University.2 In the last decade, additional 
canine blood-typing tests were made commercially avail-
able. A gel column microtube agglutination testb is based on 
agglutination of RBCs in microcolumns containing DEA 1.1 
monoclonal antibodies (Seth M, et al.: 2008, Comparison of 
gel column, card, and cartridge techniques).8 An immuno-
chromatographic membrane dipstick techniquec is based on 
the migration of RBCs on a monoclonal antibody–containing 
membrane; agglutinating erythrocytes form a visible line on 
the membrane (Seth M, et al.: 2008, Comparison of gel col-
umn, card, and cartridge techniques).
In 2011, a new canine blood-typing method was devel-
oped that consists of a one-time-use cartridge inserted into 
an analyzer and in need of only minimal user interpretation.d 
The monoclonal antibody used for the cartridge test is the 
same as the antibody used for the card test.a The objective of 
the current study was the clinical evaluation of this canine 
cartridge blood-typing system and comparison of the results 
with the gel column test.
Material and methods
Blood samples
Ninety-six blood samples were collected from 96 dogs of 40 
different breeds and of 30 mixed-breed dogs presented at the 
Small Animal Clinic, Faculty of Veterinary Medicine, Freie 
Universität Berlin (Berlin, Germany) from May through July 
2011. Eleven of the dogs were healthy blood donors, and 
85 dogs suffered from various diseases, including anemia 
(immune-mediated, blood loss, and nonregenerative ane-
mias); orthopedic, neurological, gastrointestinal, and respi-
ratory diseases; trauma; neoplasia; and others. Blood was 
drawn from the cephalic, saphenous, or jugular vein and was 
placed in a tube containing ethylenediamine tetra-acetic acid 
(EDTA) as anticoagulant. The blood samples were analyzed 
immediately or were stored up to 6 days at 4°C until blood 
type determination. The hematocrit value (Hct) or packed cell 
volume (PCV) of these samples ranged from 0.13 to 0.64 l/l 
(mean: 0.45 l/l, SD ±11.6). Twenty-five dogs were anemic 
(PCV 0.13–0.36 l/l, mean: 0.28 l/l, SD ±5.5).
Before blood typing, all samples were tested for aggluti-
nation and hemolysis. To test for agglutination, a drop of 
EDTA blood was placed on a slide and mixed with a drop of 
phosphate buffered saline (PBS) solution. If there was severe 
agglutination present, the RBCs were washed 3 times with 
PBS; if the agglutination persisted, it was considered as per-
sistent autoagglutination (n = 1). For all samples, a PCV was 
established; based on the color of the plasma, the sample was 
graded as no (n = 59), mild (n = 35), or severe (n = 2) 
hemolysis.
Cartridge test
The cartridge typing system consists of a one-time-use car-
tridged with 3 capillary channels (Fig. 1) that is used with an 
analyzer.e The cartridge is inserted into the analyzer, where it 
is heated to 37°C. After measuring the Hct, the blood sample 
was diluted with PBS according to the on-screen instruc-
tions. The proper dilution (number of diluent drops) was cal-
culated by the analyzer based on the measured Hct. 
Afterward, 100 µl of the diluted sample was added to the 
preheated cartridge (Fig. 2). The sample advances through 
the channels by capillary action. At a single site for each of 
the reaction channel and reference channel, the analyzer contin-
uously measures the intensity of light transmitted through 
the blood sample as the blood flows through each channel. 
By comparing the curve of transmitted light for the reaction 
channel and reference channel, the software determines 
whether agglutination has occurred and reports the results 
within 5 min as positive, negative, or inconclusive based on 
the presence or absence of agglutination. Inconclusive results 
are reported when the analyzer cannot make a certain clas-
sification of the sample as either DEA 1.1–positive or DEA 
1.1–negative based on features in the measured signal (Fig. 3). 
All blood-typing results are automatically archived in the 
analyzer and can be printed or exported via a network con-
nection to a Central Laboratory Information System.
Gel column test
One gel column cardb contains 6 polypropylene gel columns, 
allowing typing of 3 blood samples. The gel columns labeled 
as DEA 1.1 contain monoclonal anti–DEA 1.1 antibodies 
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(cell line 5B6) in the gel matrix. The gel matrix of the control 
column does not contain any reagents and serves as the nega-
tive control (autoagglutination control). For preparation of a 
5% RBC suspension, 500 µl of diluentf was mixed with 25 µl 
of packed RBCs. The RBC suspension was incubated for 
10 min at room temperature. Thereafter, 12.5 µl of the RBC 
suspension was added to the DEA 1.1 column and to the con-
trol column. The card was centrifuged at 80 × g for 10 min in 
a centrifuge provided by the company.g The cards were visu-
ally interpreted as follows: (0) negative, when all RBCs are 
at the bottom of the tube; 1+, when very few RBC aggluti-
nates are dispersed in the lower part of the gel, with most 
RBCs at the bottom of the tube; 2+, when all RBCs are 
agglutinated and dispersed in the gel; 3+, when some RBC 
agglutinates are dispersed in the upper part of the gel and 
most of the RBCs formed a red line on the surface of the gel; 
and 4+, when all RBCs formed a red line on top of the gel. 
Retention of ≥2+ was considered a positive test result (Seth M, 
et al.: 2008, Comparison of gel column, card, and cartridge 
techniques).8
Testing design
All tests were performed by the same laboratory technician. 
At the time of performing 50 of the 96 cartridge tests, the 
technician was blinded to the gel test result, the samples 
being labeled only by a bar code. In performing the remain-
ing 46 tests, the technician was not blinded to the gel test 
results first, but since the result of the cartridge test is deter-
mined by software, she could not affect those results.
All samples were tested first with the gel test (85 tests 
once, 10 tests twice, 1 test 3 times). Then the cartridge test 
was performed once or several times using the same samples 
(61 samples were tested once, 23 samples twice, 5 samples 
3 times, 3 samples 4 times, 2 samples 5 times, 1 sample 
6 times, and 1 sample 14 times). The positive and negative 
samples that were retested were chosen randomly. All the 
inconclusive samples were retested once or several times. 
Two analyzers were available, which were used alternately. 
For direct comparison of the results between the gel test and 
the cartridge test, the result from the first gel and first car-
tridge test typing was always used.
Agreement, sensitivity, and specificity
The sensitivity and specificity of the cartridge test were 
determined in comparison with the gel test as follows: sensi-
tivity by index of the performance of the cartridge test, cal-
culated as the percentage of dogs with a DEA 1.1–positive 
test result that are correctly classified as being positive; spec-
ificity by index of the performance of the cartridge test, 
Figure 1. QuickVet/RapidVet dog erythrocyte antigen (DEA) 1.1 blood-typing cartridge with 3 channels: a thin channel to 
detect when adequate sample has been added to the cartridge; a reaction channel with DEA 1.1–specific monoclonal antibodies and 
immunoassay stabilizer; and a reference channel with immunoassay stabilizer (contains no antibodies).
Figure 2. The diluted blood sample is added to the cartridge 
preheated in the analyzer to 37°C.
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calculated as the percentage of dogs with a DEA 1.1–negative 
test result that are correctly classified as being negative. 
Agreement was defined as the percentage of concordant 
results between the cartridge and the gel test. The 95% con-
fidence interval (CI) was calculated using BIAS.h
Results
Gel test
With the gel method, 53 dogs typed as DEA 1.1–positive 
(4+: n = 46; 3+: n = 5; 2+: n = 2) and 42 dogs as DEA 1.1 
negative (0: n = 40; weak 1+: n = 2). For 1 dog with immune-
mediated hemolytic anemia, blood typing was not possible 
due to persistent autoagglutination (control column 
positive). In 10 cases, the gel test was repeated; the results 
were always in agreement.
Cartridge test
With the cartridge test, 53 samples tested DEA 1.1 positive, 
34 samples tested DEA 1.1 negative, and 6 results were 
inconclusive (first measurement). According to the manufac-
turer’s instructions, severely hemolyzed or agglutinating 
samples cannot be used for typing with the cartridge test. 
Two blood samples were severely hemolyzed and 1 sample 
was autoagglutinating; therefore, these samples were typed 
but the results were not used for further evaluation. The dog 
with persistent agglutination of RBCs and inconclusive typ-
ing result with the gel test was positive with the cartridge test 
Figure 3. Cartridge test signals from dog erythrocyte antigen (DEA) 1.1–positive and DEA 1.1–negative blood samples as well as 
inconclusive and autoagglutinating blood samples. DEA 1.1–positive samples have an increased signal in the reaction (Main) channel and 
no signal in the reference channel (Ref). DEA 1.1–negative samples have almost identical signals in the reaction (Main) channel and the 
reference channel. Inconclusive samples have insufficient difference between the signals in the 2 channels for the analyzer software to make 
a definite decision about the blood type of the tested sample. In case of autoagglutination, there is an increased signal in the main channel 
as well as in the reference channel.
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(Fig. 3). The 2 samples that were severely hemolyzed tested 
negative with the cartridge test.
Seventeen DEA 1.1–positive samples were repeated 
between 1 and 5 times. Sixteen samples always tested posi-
tive on repeat, 1 sample was positive once and inconclusive 
once, and no positive sample tested negative on repeat. 
Eleven negative samples were repeated 1 or 2 times; all sam-
ples tested negative on repeat. Six blood samples were ini-
tially inconclusive. When retested between 1 and 13 times, 3 
were consistently inconclusive (tested 1 or 2 times), 1 was 
negative once and inconclusive 2 times, and 1 was positive 
twice and inconclusive (once) on repeat. The sixth sample 
was 7 times positive, once negative, and 5 times inconclu-
sive on repeat. If samples were tested on the 2 different ana-
lyzers available in the laboratory, there was no difference 
between the results.
Comparison of cartridge and gel test results
Table 1 shows the results of the comparison between gel test 
and cartridge test results (first measurement). Only the 
results of 93 measurements were used for the statistical eval-
uation because 2 samples were severely hemolyzed and 1 
sample was autoagglutinating. The dog with persistent 
agglutination of RBCs and inconclusive typing result with 
the gel test was positive with the cartridge test. The 2 sam-
ples that were severely hemolyzed were negative and posi-
tive with the gel test, respectively. Both samples tested 
negative with the cartridge test.
The cartridge test was in agreement with the gel test in 
90.3% (84/93) of all measurements (95% CI: 0.82–0.95). 
Considering only the positive or negative cartridge test 
results, the agreement between both test methods amounted 
to 96.5% (84/87; 95% CI: 0.90–0.99). The sensitivity was 
96.2% (50/52) with a 95% CI of 0.87–1.00. The specificity 
was 82.9% (34/41; 95% CI: 0.68–0.93) if all measurements 
were taken into account. The sensitivity and specificity for 
samples that were definitely typed by both systems were 
100.0% (50/50; 95% CI: 0.94–1.00) and 91.9% (34/37; 95% 
CI: 0.78–0.98), respectively.
Practicability of the cartridge test
To perform the cartridge test, the PCV has to be determined 
because the blood sample has to be diluted accordingly. 
Moreover, the samples have to be tested for hemolysis and 
agglutination. The procedure itself takes 10 min (preheating, 
reading of the results). User test performance and interpreta-
tion of the cartridge test are software-directed and it is there-
fore easy to use. The test result is given by the analyzer and 
does not require user interpretation.
Discussion
The cartridge test evaluated in the current study is the first 
automated blood-typing test in veterinary medicine. The 
cartridge test principle is based on the difference in the 
absorption properties of plasma and RBCs (hemoglobin). 
In the reference channel, there are RBCs suspended in 
plasma in a homogeneous way. In the test channel, for sam-
ples negative for DEA 1.1, there are also RBCs suspended 
in plasma in a homogenous way. In a test channel for sam-
ples positive for DEA 1.1, the fact that agglutinates exist 
means there are plasma segments in the channel that con-
tain fewer or no RBCs.
In contrast with the other test systems available, no user 
interpretation is necessary. However, the user has to follow 
strict preanalytical guidelines. Determination of Hct is needed 
to perform correct dilution of the sample, and the user is 
required to visually inspect the plasma for hemolysis. If a blood 
sample has not been sufficiently diluted prior to being added to 
the cartridge, the analyzer might not be able to distinguish 
between a high concentration of RBCs in the reference channel 
and the agglutinates in the test channel. This can lead to a false-
negative test result. According to the manufacturer, the test is 
robust against deviations of 1 drop from the number of droplets 
calculated to be required (not evaluated in the present study).
Severe agglutination or hemolysis will impede correct 
interpretation of the results because autoagglutination can 
lead to a false-positive result and severe hemolysis to a false-
negative result. According to the manufacturer, the software 
identifies severe agglutination and aborts the test with an 
advisory note. This software was not available at the time of 
testing. The RBCs can be washed with physiological saline; 
if the agglutination breaks up, the blood-typing test can be 
performed. Severely hemolytic samples should not be used, 
as the analyzer is unable to distinguish between the absorp-
tion of the hemolyzed plasma in the reference channel and 
any agglutinates in hemolyzed plasma in the test channel. In 
the present study, mildly hemolytic samples led to accurate 
results. A severely hemolytic sample, however, was typed 
negative when the gel test was positive.
Table 1. Dog erythrocyte antigen 1.1 blood typing results of 
the gel test and the cartridge test (results from the first gel and first 
cartridge test typing were used).*
Gel test
Cartridge test Negative Positive Total
Negative 34 0 34 (36.5)
Positive 3 50 53 (57)
Inconclusive 4 2 6 (6.5)
Total 41 (44.1) 52 (55.9) 93 (100)
* Numbers in parentheses are percentages. The gel test consisted of the ID-
Gel Test Canine DEA 1.1 (DiaMed AG, Cressier sur Morat, Switzerland). 
The cartridge test consisted of the QuickVet/RapidVet DEA 1.1 Blood 
Typing Cartridge (Scandinavian Micro Biodevices ApS, Farum, Denmark).
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The agreement between the cartridge and the gel test, 
which is considered the standard typing method for compari-
son, amounted to 90.3% (84/93); when the inconclusive 
samples were not taken into account, the agreement was 
96.5% (84/87). In a 2008 published abstract (Seth M, et al.: 
2008, Comparison of gel column, card, and cartridge tech-
niques), 3 canine DEA 1.1 blood-typing assays (the gel test 
used in the current study, a card agglutination assay, and an 
immunochromatographic method) were compared. Identical 
typing results were only obtained in 84% of cases by all 
methods.
When the inconclusive samples were not considered, the 
specificity of the cartridge test compared with the gel test 
was 91.9%. The correct identification of DEA 1.1–negative 
recipients is very important to prevent sensitization of a neg-
ative dog with DEA 1.1–positive blood. When screening 
blood donors, the sensitivity, which was 100% with the car-
tridge test, is more important, as DEA 1.1–positive donors 
should not be misidentified as being DEA 1.1 negative.
Overall, there was a good agreement between the 2 meth-
ods in the present study, but test result discrepancies were 
seen. Differences in the monoclonal antibodies used by the 
2 systems may be the cause for contradictory results. In 
3 cases, the gel test was negative when the cartridge test was 
positive. Two of these samples were also tested with the card 
test, which uses the same antibody as the cartridge test.2 The 
results were in both cases positive (2+, 3+; data not shown). 
When 23 canine samples were tested with the card test and 
the gel tube test in an earlier study,8 13 were positive with the 
card but only 9 were positive with the gel tube test. The MSU 
(Michigan State University) test classified these 4 dogs as 
DEA 1.2 positive. The conclusion of this study was that the 
card test may produce weak reactions with blood from DEA 
1.2–positive dogs.8 In the present study, however, the card 
test results were strong; therefore, a DEA 1.2 reaction caus-
ing the positive result with the card and cartridge test and the 
negative result with the gel tube seemed less likely.
Six samples were tested as inconclusive. If the user is 
convinced that the sample quality is sufficient and the testing 
(e.g., the dilution step) was performed correctly, it is recom-
mended to test the dog with another method (e.g., in a refer-
ence laboratory). A repetition of a sample for which the 
cartridge test was correctly performed is not recommended 
based on the present data. For inconclusive samples, the soft-
ware of the cartridge test analyzer gives a clinical guideline 
regarding transfusion decisions. If a donor is tested inconclu-
sively, it should be considered DEA 1.1 positive in order to 
prevent sensitization of a DEA 1.1–negative patient. 
However, if a recipient is tested inconclusively, the dog 
should only receive DEA 1.1–negative RBCs.6 Three of 6 
inconclusive samples were consistently inconclusive. One 
sample with a negative gel test result was inconclusive twice 
and negative twice with the cartridge test. Another sample 
(gel test negative) was inconclusive twice and positive twice. 
The sixth sample was negative with the gel test and either 
inconclusive, positive, or negative with the cartridge test. 
Inconclusive tests might be analogous to a 0.5+ or 1+ result 
in other typing systems such as gel tube or card systems 
(Seth M, et al.: 2008, Comparison of gel column, card, and 
cartridge techniques).8,11 The 2 dogs that had a weak 1+ reaction 
with the gel test had inconclusive results with the cartridge 
method.
In conclusion, the cartridge test was suitable for in-house 
DEA 1.1 blood typing, but there were some discrepancies 
compared with the results of the gel method. The cartridge 
test is software directed, is easy to use, and does not require 
user interpretation, but strict preanalytical guidelines have to 
be followed. For inconclusive results, an alternate blood-
typing method should be performed.
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